89Zr‐Labeled DFO@Durvalumab‐HSA nanoparticles: In vitro potential for triple‐negative breast cancer

Ähnliche Einträge

• Upregulation of FGF9 and NOVA1 in cancer‐associated fibroblasts promotes cell proliferation, invasion and migration of triple negative breast cancer
  von: Bo Zhang, et al.
  Veröffentlicht: (2024)
• Exploring chromone‐2‐carboxamide derivatives for triple‐negative breast cancer targeting EGFR, FGFR3, and VEGF pathways: Design, synthesis, and preclinical insights
  von: Dalia S. El‐Gamil, et al.
  Veröffentlicht: (2024)
• MW‐19, a dihydropyrazole derivative, induces human triple‐negative breast cancer cell apoptosis by targeting apoptosis‐related pathways
  von: Nanting Zou, et al.
  Veröffentlicht: (2024)
• Synthesis and Biological Evaluation of π‐Conjugated Ir(III) Complexes: Cytotoxic Potential, DNA/HSA Binding, Thermodynamics, and Antioxidant Activity
  von: Bhumika Joshi, et al.
  Veröffentlicht: (2025)
• Pyrrolidine‐2‐carbonitrile Derivatives as Multifunctional Antidiabetic Agents: Inhibition of α ‐Amylase, α ‐Glucosidase, and DPP‐IV With Structure‐Activity Relationships, HSA Binding, and Molecular Docking Studies
  von: Aeyaz Ahmad Bhat, et al.
  Veröffentlicht: (2025)